Recent Updates
Recently added Catalysts
AMRN Positive Sentiment

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

Friday, August 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Amarin Corporation presented new data at the ESC Congress 2026, indicating that highly adherent patients who ceased Icosapent Ethyl treatment still experience significant cardiovascular benefits. The analysis supports a 30% relative risk reduction in adverse cardiovascular events, suggesting a potential legacy effect in secondary prevention patients.

Market Sentiment Analysis

POSITIVE FACTORS

  • Data shows approximately 30% relative risk reduction in cardiovascular events.
  • Evidence suggests a potential legacy effect for secondary prevention patients.
  • Findings support the benefits of Icosapent Ethyl treatment even after cessation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+40%
120-day peak, hindsight
Typical move
5.6%
average across 2 past catalysts
Lead asset
Icosapent ethyl
Phase 3 · COVID19

Full Press Release Details

Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy Effect in Secondary Prevention Patients After Treatment Discontinuation DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation

Frequently Asked Questions

What was presented at the ESC Congress 2026?

Amarin presented data showing persistent cardiovascular benefits after Icosapent Ethyl treatment cessation.

What is the relative risk reduction reported?

The analysis indicates a 30% relative risk reduction among highly adherent patients.

What does the data suggest about treatment cessation?

The findings suggest a potential legacy effect in secondary prevention patients after treatment discontinuation.

Who conducted the analysis presented at the congress?

The analysis was conducted by Amarin Corporation.

ShareAdd on Google
Tags: AMRN Viatris Investor Conferences Healthcare Amarin Corporation Icosapent Ethyl cardiovascular benefit ESC Congress 2026 REDUCE-IT
Last updated: Aug 28, 2026

Biotech snapshot

Cash runway
$315M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Icosapent ethylPhase 3
COVID19 →

Catalyst track record

+40%
best trade around AMRN's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for AMRN.

See every catalyst's timing & PoA →